Peptides & Amino Acids

Secondary SIL peptide for Dupilimab detection and quantification

Primary SIL peptide for Dinutuximab detection and quantification

Secondary SIL peptide for Dinutuximab detection and quantification

SIL peptide for Vedolozumab detection and quantification

Primary SIL peptide for Emicizumab  detection and quantification

Secondary SIL peptide for Emicizumab  detection and quantification

SIL peptide for Infliximab detection and quantification

OVA 257 264 peptide (SIINFEKL) conjugated to KLH Ovalbumin protein Ovalbumin (Uniprot P01012) is the major component of egg white. It has been demonstrated that Ovalbumin contains B-cell epitopes which are recognized by specific IgE antibodies and CD4 T cell epitopes restricted by the MHC I-Ad molecule in mice and by HLA-D molecule in human such as OVA(257-264). Applications of OVA 257-264 OVA 257-264 is used to stimulate T cells in PBMCs and to quantify peptide epitope specificity and IFN-γ releasing effector cells by ELISPOT assay. OVA 257-264 is also used to test new adjuvant in immunotherapeutic vaccine development. OVA 257-264 can form a stable hydrogel and stimulate a immune response. This reaction seems to be linked with OVA 257-264 property to self-assemble into a hydrogel. OVA 257-264 KLH conjugate Keyhole limpet hemocyanin (KLH) is a carrier protein which enhances immune response against haptens conjugated to it. SB-PEPTIDE has a long experience in haptens / carrier prot

TET 830 modified/T-helper epitope from tetanus toxoid – AQYIKANSKFIGITEL Tetanus Tetanus is a life-threatening condition caused by Clostridium tetani bacteria. After entering the body through a break in the skin, they produce a toxin that causes convulsions and severe muscle spasms, that can be strong enough to fracture bones of the spin. Tetanus toxin inhibits neurotransmitter release by binding to peripheral neuronal synapses. The substance will then be internalized and transported to the spinal cord where it will be able to move between postsynaptic and presynaptic neurons. For the time being, there is no cure for tetanus. Indeed, the extreme potency of the tetanospasmin toxin prevents immunity in infected people, leading to 30-40% deaths among this population. Symptoms usually start 4 to 21 days after infection, and most of the people get them after about 10 days. Tetanus vaccine Thanks to the widespread use of tetanus vaccines, infections are rare in many countries.